Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder

Full text
Author(s):
de Almeida, Carlos M. O. [1] ; Brito, Manuelina M. C. [2] ; Bosaipo, Nayanne B. [2] ; Pimentel, Angela V. [2] ; Tumas, Vitor [2] ; Zuardi, Antonio W. [2, 3] ; Crippa, Jose A. S. [2, 3] ; Hallak, Jaime E. C. [2, 3] ; Eckeli, Alan L. [2]
Total Authors: 9
Affiliation:
[1] State Univ Amazonas, Sch Hlth Sci, Manaus, Amazonas - Brazil
[2] Univ Sao Paulo, Fac Med Ribeirao Preto, Div Neurol, Dept Neurosci & Sci Behav, Sao Paulo - Brazil
[3] CNPq FAPESP CAPES, Natl Inst Sci & Technol Translat Med, Sao Paulo - Brazil
Total Affiliations: 3
Document type: Journal article
Source: MOVEMENT DISORDERS; v. 36, n. 7, p. 1711-1715, JUL 2021.
Web of Science Citations: 0
Abstract

Background REM sleep behaviour disorder (RBD) is a common non-motor feature of Parkinson's disease (PD). Cannabidiol (CBD) is one of the main non-psychoactive components of Cannabis sativa and may represent an alternative route for treating RBD. Objective This study assessed the efficacy and safety of CBD for RBD in PD. Methods We conducted a phase II/III, double-blind, placebo-controlled clinical trial in 33 patients with RBD and PD. Patients were randomized 1:1 to CBD in doses of 75 to 300mg or matched capsules placebo and were followed up for 14 weeks. The primary outcomes were the frequency of nights with RBD, CGI-I, and CGI-S. Results CBD showed no difference to placebo for primary outcomes. Regarding secondary outcomes, we observed a significant improvement in average sleep satisfaction from the 4th to 8th week in the CBD versus placebo group with P = 0.049 and P = 0.038, respectively. Conclusion CBD, as an adjunct therapy, showed no reduction in RBD manifestations in PD patients. A transient improvement in sleep satisfaction with a dose of 300mg has been noted. (c) 2021 International Parkinson and Movement Disorder Society (AU)

FAPESP's process: 08/09009-2 - Crack/cocaine chronic use: dopamine transporters availability, genetic factors, and executive functioning
Grantee:Acioly Luiz Tavares de Lacerda
Support Opportunities: Regular Research Grants